Mesenchymal stem cell therapy for bronchopulmonary dysplasia and haemorrhage - Medipost

Drug Profile

Mesenchymal stem cell therapy for bronchopulmonary dysplasia and haemorrhage - Medipost

Alternative Names: Pneumostem

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medipost
  • Developer Medipost; Samsung Medical Center
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bronchopulmonary dysplasia
  • New Molecular Entity No
  • Available For Licensing Yes - Bronchopulmonary dysplasia

Highest Development Phases

  • Phase II Bronchopulmonary dysplasia; Haemorrhage

Most Recent Events

  • 28 Mar 2017 Phase-II clinical trials in Haemorrhage (In neonates) in South Korea (unspecified route) (NCT02890953)
  • 13 Sep 2016 Samsung Medical Center plans a phase II trial for Haemorrhage (In neonates) in South Korea (NCT02890953)
  • 03 May 2016 Medipost has patent protection for mesenchymal stem cells therapy for bronchopulmonary dysplasia in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top